Abstract
Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) are valuable diagnostic tools for patients with neuroendocrine tumours (NETs). To date, a meta-analysis about the diagnostic accuracy of these imaging methods is lacking. Aim of our study is to meta-analyse published data about the diagnostic performance of SMSR PET or PET/CT in patients with thoracic and/or gastroenteropancreatic (GEP) NETs. A comprehensive computer literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases through October 2011 and regarding SMSR PET or PET/CT in patients with NETs was carried out. Only studies in which SMSR PET or PET/CT were performed in patients with thoracic and/or GEP NETs were selected (medullary thyroid tumours and neural crest derived tumours were excluded from the analysis). Pooled sensitivity, pooled specificity and area under the ROC curve were calculated to measure the diagnostic accuracy of SMSR PET and PET/CT in NETs. Results: Sixteen studies comprising 567 patients were included in this meta-analysis. The pooled sensitivity and specificity of SMSR PET or PET/CT in detecting NETs were 93% (95% confidence interval [95% CI]: 91–95%) and 91% (95% CI: 82–97%), respectively, on a per patient-based analysis. The area under the ROC curve was 0.96. In patients with suspicious thoracic and/or GEP NETs, SMSR PET and PET/CT demonstrated high sensitivity and specificity. These accurate techniques should be considered as first-line diagnostic imaging methods in patients with suspicious thoracic and/or GEP NETs.
Similar content being viewed by others
References
A. Faggiano, P. Ferolla, F. Grimaldi, D. Campana, M. Manzoni, M.V. Davì, A. Bianchi, R. Valcavi, E. Papini, D. Giuffrida, D. Ferone, G. Fanciulli, G. Arnaldi, G.M. Franchi, G. Francia, G. Fasola, L. Crino, A. Pontecorvi, P. Tomassetti, A. Colao, Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: the net management study. J. Endocrinol. Invest. (2011). doi:10.3275/8102
G. Rindi, B. Wiedenmann, Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat. Rev. Endocrinol. 8, 54–64 (2011)
V. Ambrosini, M. Fani, S. Fanti, F. Forrer, H.R. Maecke, Radiopeptide imaging and therapy in Europe. J. Nucl. Med. 52(Suppl 2), 42S–55S (2011)
M.M. Graham, Y. Menda, Radiopeptide imaging and therapy in the United States. J. Nucl. Med. 52(Suppl 2), 56S–63S (2011)
V. Rufini, M.L. Calcagni, R.P. Baum, Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36, 228–247 (2006)
D.J. Kwekkeboom, E.P. Krenning, K. Scheidhauer, V. Lewington, R. Lebtahi, A. Grossman, P. Vitek, A. Sundin, Mallorca consensus conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 90, 184–189 (2009)
A.I. Vinik, E.A. Woltering, R.R. Warner, M. Caplin, T.M. O’Dorisio, G.A. Wiseman, D. Coppola, North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39, 713–734 (2010)
N.F. Schreiter, W. Brenner, M. Nogami, R. Buchert, A. Huppertz, U.F. Pape, V. Prasad, B. Hamm, M.H. Maurer, Cost comparison of (111)In-DTPA-octreotide scintigraphy and (68)Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 39, 72–82 (2012)
J. Zamora, V. Abraira, A. Muriel, K. Khan, A. Coomarasamy, Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med. Res. Methodol. 6, 31 (2006)
M. Hofmann, H. Maecke, R. Börner, E. Weckesser, P. Schöffski, L. Oei, J. Schumacher, M. Henze, A. Heppeler, J. Meyer, H. Knapp, Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28, 1751–1757 (2001)
S. Koukouraki, L.G. Strauss, V. Georgoulias, J. Schuhmacher, U. Haberkorn, N. Karkavitsas, A. Dimitrakopoulou-Strauss, Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 460–466 (2006)
M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovacs, E. Von Guggenberg, R. Bale, I.J. Virgolini, 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508–518 (2007)
I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz, M. Schäfer, T. Schilling, S. Haufe, T. Herrmann, U. Haberkorn, Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 34, 1617–1626 (2007)
I. Kayani, J.B. Bomanji, A. Groves, G. Conway, S. Gacinovic, T. Win, J. Dickson, M. Caplin, P.J. Ell, Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112, 2447–2455 (2008)
V. Ambrosini, P. Tomassetti, P. Castellucci, D. Campana, G. Montini, D. Rubello, C. Nanni, A. Rizzello, R. Franchi, S. Fanti, Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35, 1431–1438 (2008)
V. Ambrosini, P. Castellucci, D. Rubello, C. Nanni, A. Musto, V. Allegri, G.C. Montini, S. Mattioli, G. Grassetto, A. Al-Nahhas, R. Franchi, S. Fanti, 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 30, 281–286 (2009)
I. Kayani, B.G. Conry, A.M. Groves, T. Win, J. Dickson, M. Caplin, J.B. Bomanji, A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50, 1927–1932 (2009)
A. Haug, C.J. Auernhammer, B. Wängler, R. Tiling, G. Schmidt, B. Göke, P. Bartenstein, G. Pöpperl, Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36, 765–770 (2009)
A. Frilling, G.C. Sotiropoulos, A. Radtke, M. Malago, A. Bockisch, H. Kuehl, J. Li, C.E. Broelsch, The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann. Surg. 252, 850–856 (2010)
T. **dal, A. Kumar, B. Venkitaraman, R. Dutta, R. Kumar, Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J. Intern. Med. 25, 386–391 (2010)
Y. Krausz, N. Freedman, R. Rubinstein, E. Lavie, M. Orevi, S. Tshori, A. Salmon, B. Glaser, R. Chisin, E. Mishani, D. Gross J, 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). Mol. Imaging Biol. 13, 583–593 (2011)
R. Srirajaskanthan, I. Kayani, A.M. Quigley, J. Soh, M.E. Caplin, J. Bomanji, The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J. Nucl. Med. 51, 875–882 (2010)
A. Versari, L. Camellini, G. Carlinfante, A. Frasoldati, F. Nicoli, E. Grassi, C. Gallo, F.P. Giunta, A. Fraternali, D. Salvo, M. Asti, F. Azzolini, V. Iori, R. Sassatelli, Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin. Nucl. Med. 35, 321–328 (2010)
J. Ruf, J. Schiefer, C. Furth, O. Kosiek, S. Kropf, F. Heuck, T. Denecke, M. Pavel, A. Pascher, B. Wiedenmann, H. Amthauer, 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J. Nucl. Med. 52, 697–704 (2011)
N. Naswa, P. Sharma, A. Kumar, A.H. Nazar, R. Kumar, S. Chumber, C. Bal, Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am. J. Roentgenol. 197, 1221–1228 (2011)
K.I. Alexandraki, G. Kaltsas, Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 41, 40–52 (2012)
K.L. Yim, Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine 40, 181–186 (2011)
H. Xu, M. Zhang, G. Zhai, M. Zhang, G. Ning, B. Li, The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine 36, 385–391 (2009)
T.D. Poeppel, I. Binse, S. Petersenn, H. Lahner, M. Schott, G. Antoch, W. Brandau, A. Bockisch, C. Boy, 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J. Nucl. Med. 52, 1864–1870 (2011)
D. Wild, B.J. Bomanji, J.C. Reubi, H.R. Maecke, M.E. Caplin, P.J. Ell, Comparison of 68Ga-DOTA-NOC and 68Ga-DOTA-TATE PET/CT in the detection of GEP NETs. Eur. J. Nucl. Med. Mol. Imaging 36(Suppl 2), S201 (2009)
Acknowledgment
Authors are grateful to Ms. Barbara Muoio for her technical support in bibliographic research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Treglia, G., Castaldi, P., Rindi, G. et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42, 80–87 (2012). https://doi.org/10.1007/s12020-012-9631-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9631-1